Abstract Body

In order to assess the impact of HIV prevention strategies, it is critical to measure the rate at which new HIV infections are occurring in populations. To achieve needed performance requirements (e.g., long ‘mean duration of recent infection’ [MDRI], low ‘false recent rate’ [FRR]), most programs currently use multi-assay algorithms including avidity-modified antibody and viral load measurements. MULTI-ARRAY® is a high throughput technology with a wide dynamic range and low non-specific binding that has been used successfully in a variety of applications. We determined feasibility of an improved multiplex HIV incidence assay to discriminate recent from longstanding HIV infection using the MULTI-ARRAY platform.

Using MULTI-ARRAY technology, we measured antibody quantity and avidity to ten HIV proteins. A total of 28 assays were run: standard serology assays with and without disrupting agent, and an assay format with anti-human IgG capture and detection with SULFO-TAG™ labeled HIV antigens. 96 samples were tested: 75 samples from the CEPHIA Developmental set (http://www.incidence-estimation.com/cephiaqueries/cephiaDB/overview), 15 samples from the SeraCare Incidence/Prevalence Performance Panel, and additional samples from apparently healthy individuals.

Several assays could discriminate recent from longstanding HIV infection even as stand-alone markers if samples from Elite Controllers were excluded: the standard serology format with and without pretreatment for gp120 and gp160, and the antibody capture format for gp120 showed 100% sensitivity and 100% specificity in this sample set. In a ROC analysis, 13 assays had ROC areas of 0.90 or better (elite controllers excluded). None of the tested antibody assays was able to discriminate elite controllers; thus including a (antigen or nucleic acid) viral load assay would be required. The time dependence of the gp120 and gp160 ECL signal as function of time from seroconversion indicates that the signal continues to increase even after two years, indicating that determining an MDRI of well over a year at a low FRR is feasible.

Assays to discriminate recent from longstanding HIV infection have been developed in a 96-well high-throughput assay format for the MESO® SECTOR S 600 Imager and the MESO QuickPlex® SQ 120.